These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8949314)

  • 21. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system.
    Guo X; Saini HK; Wang J; Gupta SK; Goyal RK; Dhalla NS
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):717-32. PubMed ID: 16076281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to explain the differences between renin angiotensin system modulators.
    Levy BI
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):134S-141S. PubMed ID: 16125050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
    Lévy S
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renin-angiotensin system modulation: the weight of evidence.
    Brown B; Hall AS
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):127S-133S. PubMed ID: 16125049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
    Palmieri V; Devereux RB
    Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the optimal medical management of ischemic heart failure?
    Cleland JG; Alamgir F; Nikitin NP; Clark AL; Norell M
    Prog Cardiovasc Dis; 2001; 43(5):433-55. PubMed ID: 11251129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
    van Gilst WH; Warnica JW; Baillot R; Johnstone D; Calciu CD; Block P; Myers MG; Chocron S; Rouleau JL;
    Am Heart J; 2006 Jun; 151(6):1240-6. PubMed ID: 16781228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction.
    Sander GE; McKinnie JJ; Greenberg SS; Giles TD
    Prog Cardiovasc Dis; 1999; 41(4):265-300. PubMed ID: 10362349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?
    Fox K; Ferrari R; Yusuf S; Borer JS
    Eur Heart J; 2006 Sep; 27(18):2154-7. PubMed ID: 16905555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular protection: current possibilities and future perspectives.
    Lüscher TF
    Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.
    Papademetriou V
    Am Heart J; 2009 Jun; 157(6 Suppl):S24-30. PubMed ID: 19450721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.
    Young JB
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):89-102. PubMed ID: 7786840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Resistance to ACE inhibitors. Myth or reality?].
    Aumont MC; Juliard JM
    Arch Mal Coeur Vaiss; 2001 Sep; 94(9):1008-12. PubMed ID: 11603063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left ventricular hypertrophy and heart failure in women.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.